Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a clinical study titled A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease. The study aims to evaluate the safety and efficacy of AMG 732, a potential treatment for Thyroid Eye Disease (TED), in both healthy participants and those with the condition.
The intervention being tested is AMG 732, administered via subcutaneous injection. It is designed to assess the safety in single doses and the efficacy in multiple doses for treating TED.
This interventional study is randomized and sequential, with a double-masked design to ensure unbiased results. The primary purpose is treatment-focused, involving both experimental and placebo groups.
The study began on May 2, 2024, with an estimated primary completion date yet to be provided. The latest update was submitted on July 25, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly impact Amgen’s stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the TED treatment market.
The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.